Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TRANSLATE BIO, INC.

(TBIO)
Delayed Quote. Delayed Nasdaq - 09/13 04:00:00 pm
37.36 USD   -0.13%
09/15TRANSLATE BIO : LifeSci Index Partners
AQ
09/15INSIDER SELL : Translate Bio
MT
09/14TRANSLATE BIO : Sanofi Completes Translate Bio Buyout
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/09/2021 09/10/2021 09/13/2021 09/14/2021 09/13/2021 Date
37.48(c) 37.41(c) 37.36(c) 0(c) 37.36 Last
927 159 584 745 1 352 369 34 832 1 352 369 Volume
-0.19% -0.19% -0.13% -100.00% -0.13% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 157 M - -
Net income 2021 39,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 76,2x
Yield 2021 -
Sales 2022 98,1 M - -
Net income 2022 -89,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 20,5x
Yield 2022 -
Capitalization 2 824 M 2 824 M -
Capi. / Sales 2021 18,0x
Capi. / Sales 2022 28,8x
Nbr of Employees 122
Free-Float 92,6%
More Financials
Company
Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or... 
More about the company
Ratings of Translate Bio, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about TRANSLATE BIO, INC.
09/15TRANSLATE BIO : LifeSci Index Partners
AQ
09/15INSIDER SELL : Translate Bio
MT
09/14TRANSLATE BIO : Sanofi Completes Translate Bio Buyout
MT
09/14TRANSLATE BIO, INC. : Completion of Acquisition or Disposition of Assets, Notice..
AQ
09/14TRANSLATE BIO, INC.(NASDAQGS : TBIO) dropped from NASDAQ Composite Index
CI
09/13TRANSLATE BIO, INC.(NASDAQGS : TBIO) dropped from NASDAQ Biotechnology Index
CI
09/09TRANSLATE BIO : Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
09/08TRANSLATE BIO : Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AQ
09/02VC DAILY : Laronde Fundraising Haul Reflects -2-
DJ
09/02VC DAILY : Laronde Fundraising Haul Reflects Search for Next Moderna
DJ
08/16SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Tra..
PR
08/06SANOFI : Bionity - Sanofi to acquire Translate Bio
AQ
08/06TRANSLATE BIO : Announces Second Quarter 2021 Financial Results and Provides Cor..
AQ
08/05Translate Bio Announces Second Quarter 2021 Financial Results and Provides Co..
GL
08/05Translate Bio, Inc. Reports Earnings Results for the Second Quarter Ended Jun..
CI
More news
News in other languages on TRANSLATE BIO, INC.
09/08SANOFI : le français rachète Kadmon pour 1,9 milliard de dollars
09/08PLANÈTE BOURSE : La revue de presse du mercredi 8 septembre 2021
09/08Sanofi achète la biotech américaine Kadmon pour $1,9 milliard
08/03MÄRKTE USA/Optimismus treibt Anleger in Aktien
08/03MÄRKTE USA/Wall Street dreht ins Plus - Optimismus überwiegt
More news
Analyst Recommendations on TRANSLATE BIO, INC.
More recommendations
Chart TRANSLATE BIO, INC.
Duration : Period :
Translate Bio, Inc. Technical Analysis Chart | TBIO | US89374L1044 | MarketScreener
Technical analysis trends TRANSLATE BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Ronald C. Renaud Chairman & Chief Executive Officer
E. Rand Sutherland President
Brendan Smith Chief Financial Officer & Head-Corporate Strategy
Ann Barbier Chief Medical Officer
Richard Wooster Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
TRANSLATE BIO, INC.0.00%2 824
BIONTECH SE357.13%90 003
GILEAD SCIENCES, INC.22.43%89 434
REGENERON PHARMACEUTICALS35.20%67 910
WUXI APPTEC CO., LTD.28.41%65 728
VERTEX PHARMACEUTICALS-20.83%48 539